| P50 | author | Ana Lúcia S Rodrigues | Q41090877 |
| P2093 | author name string | Anderson Camargo | |
| P2860 | cites work | Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway | Q47616820 |
| | Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression. | Q47633542 |
| | A brief history of antidepressant drug development: from tricyclics to beyond ketamine | Q47640228 |
| | TNF-α-induced depressive-like phenotype and p38(MAPK) activation are abolished by ascorbic acid treatment | Q47663689 |
| | Evidence for the involvement of opioid system in the antidepressant-like effect of ascorbic acid. | Q47683528 |
| | Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration | Q47811548 |
| | Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway | Q47832884 |
| | Protective effects of guanosine against sepsis-induced damage in rat brain and cognitive impairment | Q47911475 |
| | The activation of α1-adrenoceptors is implicated in the antidepressant-like effect of creatine in the tail suspension test. | Q47920566 |
| | Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex | Q47939452 |
| | Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). | Q47964049 |
| | Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide-cGMP and PI3K/mTOR pathways. | Q47978385 |
| | Cingulate and thalamic metabolites in obsessive-compulsive disorder | Q48051783 |
| | Involvement of PI3K/Akt Signaling Pathway and Its Downstream Intracellular Targets in the Antidepressant-Like Effect of Creatine. | Q48083788 |
| | Evidence for the involvement of 5-HT1A receptor in the acute antidepressant-like effect of creatine in mice | Q48192922 |
| | Effects of guanine nucleotides on adenosine and glutamate modulation of cAMP levels in optic tectum slices from chicks | Q48194906 |
| | Dual serotonergic signals: a key to understanding paradoxical effects? | Q48403214 |
| | Regional localization of agmatine in the rat brain: an immunocytochemical study | Q48456543 |
| | MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions. | Q48483209 |
| | Guanosine prevents behavioral alterations in the forced swimming test and hippocampal oxidative damage induced by acute restraint stress | Q48484990 |
| | Guanosine Prevents Anhedonic-Like Behavior and Impairment in Hippocampal Glutamate Transport Following Amyloid-β1-40 Administration in Mice | Q48528502 |
| | Exocytotic release of creatine in rat brain | Q48529509 |
| | Antidepressant-like effect of creatine in mice involves dopaminergic activation. | Q48666146 |
| | Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress | Q48788833 |
| | Neuroprotection Promoted by Guanosine Depends on Glutamine Synthetase and Glutamate Transporters Activity in Hippocampal Slices Subjected to Oxygen/Glucose Deprivation | Q48921203 |
| | The antidepressant-like effect of chronic guanosine treatment is associated with increased hippocampal neuronal differentiation | Q48970988 |
| | Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals | Q49024727 |
| | Agmatine protects against intracerebroventricular streptozotocin-induced water maze memory deficit, hippocampal apoptosis and Akt/GSK3β signaling disruption. | Q50667544 |
| | Guanosine controls inflammatory pathways to afford neuroprotection of hippocampal slices under oxygen and glucose deprivation conditions. | Q50955863 |
| | Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats. | Q50969954 |
| | The synthesis of creatine by the brain of the intact rat. | Q51300988 |
| | Agmatine produces antidepressant-like effects by activating AMPA receptors and mTOR signaling. | Q52141192 |
| | Guanosine Exerts Neuroprotective Effect in an Experimental Model of Acute Ammonia Intoxication. | Q52141755 |
| | Mental depression in hypertensive patients treated for long periods with large doses of reserpine. | Q52173297 |
| | Agmatine potentiates neuroprotective effects of subthreshold concentrations of ketamine via mTOR/S6 kinase signaling pathway. | Q54109744 |
| | Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. | Q54353114 |
| | Neuroprotective effect of guanosine against glutamate-induced cell death in rat hippocampal slices is mediated by the phosphatidylinositol-3 kinase/Akt/ glycogen synthase kinase 3β pathway activation and inducible nitric oxide synthase inhibition. | Q54581993 |
| | Antidepressant effects of creatine on amyloid β1-40-treated mice: The role of GSK-3β/Nrf2 pathway. | Q54979220 |
| | Creatine: a miserable life without it. | Q55020079 |
| | Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. | Q55054440 |
| | Involvement of PKA, PKC, CAMK-II and MEK1/2 in the acute antidepressant-like effect of creatine in mice. | Q55073616 |
| | Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. | Q55438088 |
| | Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients | Q58213311 |
| | Protective Effect of the Energy Precursor Creatine Against Toxicity of Glutamate and β-Amyloid in Rat Hippocampal Neurons | Q58829455 |
| | Neuromodulatory Effects of Guanine-Based Purines in Health and Disease | Q59127756 |
| | Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine | Q59282050 |
| | Plasma Agmatine and Platelet Imidazoline Receptors in Depressiona | Q59588569 |
| | The catecholamine hypothesis of affective disorders: a review of supporting evidence | Q22306296 |
| | mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E | Q24301780 |
| | Depressogenic effects of medications: a review | Q24635465 |
| | mTOR signaling: at the crossroads of plasticity, memory and disease | Q24647655 |
| | Ketamine use in current clinical practice | Q26750682 |
| | Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders | Q28072158 |
| | Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release | Q28111965 |
| | New approaches to antidepressant drug discovery: beyond monoamines | Q28293089 |
| | Distribution of creatine, guanidinoacetate and the enzymes for their biosynthesis in the animal kingdom. Implications for phylogeny | Q28769562 |
| | Antidepressant effects of ketamine in depressed patients | Q29617327 |
| | A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 |
| | mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists | Q29618120 |
| | Rat brain guanosine binding site. Biological studies and pseudo-receptor construction. | Q31029356 |
| | Normal metabolite levels in the left dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: a single voxel (1)H spectroscopy study | Q33515865 |
| | Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter | Q33693047 |
| | Antidepressants for the new millennium | Q33709227 |
| | Depression: the case for a monoamine deficiency. | Q33896395 |
| | Ascorbate regulation and its neuroprotective role in the brain | Q33899469 |
| | Is agmatine a novel neurotransmitter in brain? | Q33901031 |
| | Risks of all-cause and suicide mortality in mental disorders: a meta-review | Q33915499 |
| | Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression | Q34112179 |
| | Functional antagonists at the NMDA receptor complex exhibit antidepressant actions | Q34196683 |
| | The biochemistry of affective disorders | Q34203596 |
| | Involvement of astrocytes in purine-mediated reparative processes in the brain | Q34264926 |
| | A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder | Q34292341 |
| | Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder | Q34451408 |
| | Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect | Q34661622 |
| | Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure | Q34744471 |
| | The potential therapeutic effect of guanosine after cortical focal ischemia in rats. | Q35109170 |
| | BDNF release is required for the behavioral actions of ketamine | Q35203597 |
| | An excitatory synapse hypothesis of depression | Q35563515 |
| | Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor | Q35566498 |
| | Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation | Q35587857 |
| | Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents | Q35754079 |
| | Agmatine protects against beta-amyloid25-35-induced memory impairments in the rat. | Q43067397 |
| | Ammonia toxicity to the brain: effects on creatine metabolism and transport and protective roles of creatine | Q43130748 |
| | Agmatine prevents LPS-induced spatial memory impairment and hippocampal apoptosis. | Q43149426 |
| | Protective effects of ascorbic acid on behavior and oxidative status of restraint-stressed mice | Q43659868 |
| | Swelling-activated taurine and creatine effluxes from rat cortical astrocytes are pharmacologically distinct | Q43916384 |
| | High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial | Q44123620 |
| | Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test | Q44349016 |
| | Antidepressant-like effect of agmatine and its possible mechanism | Q44462663 |
| | Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. | Q45063835 |
| | Effects of chronic administered guanosine on behavioral parameters and brain glutamate uptake in rats. | Q45159502 |
| | Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain | Q45258420 |
| | Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test | Q45892096 |
| | Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. | Q46014110 |
| | Nutrition and depressive symptoms in community-dwelling elderly persons in Japan | Q46106937 |
| | Effect of various antidepressant drugs on the spontaneous firing rate of locu coeruleus and dorsal raphe neurons of the rat | Q46119737 |
| | Importance of schedule of administration in the therapeutic efficacy of guanosine: early intervention after injury enhances glutamate uptake in model of hypoxia-ischemia. | Q46322199 |
| | Guanosine improves motor behavior, reduces apoptosis, and stimulates neurogenesis in rats with parkinsonism. | Q46347416 |
| | Guanosine enhances glutamate transport capacity in brain cortical slices | Q46679795 |
| | Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity | Q46723175 |
| | Guanosine Protects Against Cortical Focal Ischemia. Involvement of Inflammatory Response. | Q46814683 |
| | Neuroprotective effects of guanosine administration on behavioral, brain activity, neurochemical and redox parameters in a rat model of chronic hepatic encephalopathy. | Q46899015 |
| | Creatine monohydrate in resistant depression: a preliminary study | Q46910762 |
| | Downregulation of Egr-1 expression level via GluN2B underlies the antidepressant effects of ketamine in a chronic unpredictable stress animal model of depression | Q47222337 |
| | Acute agmatine administration, similar to ketamine, reverses depressive-like behavior induced by chronic unpredictable stress in mice | Q47373609 |
| | Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors | Q47408214 |
| | Involvement of different types of potassium channels in the antidepressant-like effect of ascorbic acid in the mouse tail suspension test | Q62015523 |
| | Antidepressant effect of vitamin C | Q71168507 |
| | GTP and guanosine synergistically enhance NGF-induced neurite outgrowth from PC12 cells | Q71462197 |
| | Extracellular guanosine and guanosine-5′-triphosphate increase: NGF synthesis and release from cultured mouse neopallial astrocytes | Q71861786 |
| | Neurite outgrowth in PC12 cells is enhanced by guanosine through both cAMP-dependent and -independent mechanisms | Q71971294 |
| | Agmatine, the bacterial amine, is widely distributed in mammalian tissues | Q72336253 |
| | Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine | Q72657098 |
| | Observed effects of creatine monohydrate in a patient with depression and fibromyalgia | Q79167038 |
| | Mechanism of guanosine-induced neuroprotection in rat hippocampal slices submitted to oxygen-glucose deprivation | Q81151883 |
| | Guanosine is neuroprotective against oxygen/glucose deprivation in hippocampal slices via large conductance Ca²+-activated K+ channels, phosphatidilinositol-3 kinase/protein kinase B pathway activation and glutamate uptake | Q83704482 |
| | Evidence of Reduced Agmatine Concentrations in the Cerebral Cortex of Suicides | Q89475552 |
| | Single administration of agmatine reverses the depressive-like behavior induced by corticosterone in mice: Comparison with ketamine and fluoxetine | Q91040595 |
| | The possible beneficial effects of creatine for the management of depression | Q91334978 |
| | Augmentation effect of ketamine by guanosine in the novelty-suppressed feeding test is dependent on mTOR signaling pathway | Q92290423 |
| | Guanosine Protects Striatal Slices Against 6-OHDA-Induced Oxidative Damage, Mitochondrial Dysfunction, and ATP Depletion | Q92994278 |
| | Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments | Q93177074 |
| | Potassium- and capsaicin-induced release of agmatine from spinal nerve terminals | Q94532847 |
| | Guanosine promotes proliferation of neural stem cells through cAMP-CREB pathway | Q95445471 |
| | Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study | Q36271087 |
| | Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study | Q36387048 |
| | Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study | Q36690533 |
| | Proposal of a guanine-based purinergic system in the mammalian central nervous system. | Q36947502 |
| | Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression | Q37137072 |
| | Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression | Q37153400 |
| | Neurotrophic effects of extracellular guanosine | Q37207104 |
| | Guanosine and its role in neuropathologies | Q37256409 |
| | Intranasal guanosine administration presents a wide therapeutic time window to reduce brain damage induced by permanent ischemia in rats. | Q38358493 |
| | Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial | Q38373713 |
| | Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder | Q38543238 |
| | The efficacy of fluoxetine as an antidepressant in the short and long term | Q38600945 |
| | Agmatine, a potential novel therapeutic strategy for depression. | Q38796299 |
| | KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. | Q38803371 |
| | Guanosine inhibits LPS-induced pro-inflammatory response and oxidative stress in hippocampal astrocytes through the heme oxygenase-1 pathway | Q38830721 |
| | Agmatine, by Improving Neuroplasticity Markers and Inducing Nrf2, Prevents Corticosterone-Induced Depressive-Like Behavior in Mice | Q38875865 |
| | Guanosine protects C6 astroglial cells against azide-induced oxidative damage: a putative role of heme oxygenase 1. | Q39011258 |
| | Agmatine enhances antidepressant potency of MK-801 and conventional antidepressants in mice | Q39065318 |
| | Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: Involvement of intracellular signaling pathways. | Q39181634 |
| | Therapeutic potential of agmatine for CNS disorders. | Q39316625 |
| | Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3β pathway. | Q39334402 |
| | Ascorbic Acid to Manage Psychiatric Disorders | Q39363527 |
| | The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study | Q39443227 |
| | Purine metabolism is dysregulated in patients with major depressive disorder | Q39788582 |
| | MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine | Q39959282 |
| | A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission | Q40566565 |
| | Guanosine stimulates neurite outgrowth in PC12 cells via activation of heme oxygenase and cyclic GMP. | Q40722484 |
| | Involvement of the agmatinergic system in the depressive-like phenotype of the Crtc1 knockout mouse model of depression | Q41271049 |
| | The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test. | Q41630586 |
| | Current perspectives on the antidepressant-like effects of guanosine. | Q41647786 |
| | Specific [(3)H]-guanosine binding sites in rat brain membranes | Q42021948 |
| | Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. | Q42259205 |
| | Guanosine prevents nitroxidative stress and recovers mitochondrial membrane potential disruption in hippocampal slices subjected to oxygen/glucose deprivation. | Q42363254 |
| | Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder. | Q42372900 |
| | Guanosine and synthetic organoselenium compounds modulate methylmercury-induced oxidative stress in rat brain cortical slices: involvement of oxidative stress and glutamatergic system | Q42448184 |
| | Rat cultured astrocytes release guanine-based purines in basal conditions and after hypoxia/hypoglycemia | Q42466571 |
| | Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. | Q42630246 |
| | Agmatine produces antidepressant-like effects in two models of depression in mice. | Q42673618 |
| | Sub-chronic agmatine treatment modulates hippocampal neuroplasticity and cell survival signaling pathways in mice. | Q42679245 |
| P304 | page(s) | 2470547019858083 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Chronic Stress | Q58213341 |
| P1476 | title | Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators | |
| P478 | volume | 3 | |